Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF as an adjuvant to hepatitis B vaccination in hemodialysis patients
ACTRN12611000246987Phase 2Not yet recruiting
- Sponsor
- Kamran Bagheri Lankarani
- Start
- Apr 2011
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of Hepatitis B vaccine and sargramostim in hepatitis B (HBV) (2 arms), sponsored by Kamran Bagheri Lankarani. Primary endpoints: Anti-HBs seroprotection after first dose and Anti-HBs seroprotection after vaccination series completion. Planned start Apr 2011; status: not yet recruiting.
02
Drugs
Hepatitis B vaccinesargramostim
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on ACTRN12611000246987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000246987.